Tom Gallagher

Max Broden said the move to a 30% of FSA reserves limit is internally set but shared with external constituents, and larger transactions would lower per-deal cost given a strengthening track record.

Dan Amos said Aflac continues to evaluate opportunities but applies a strenuous test, noting the small companies it acquired have turned around and performed better.

Max explained that while individual lapsed policies have lower IRRs, the new policies have longer expected duration, creating a balancing effect with minimal net impact.

Dan confirmed the JPY 90B threshold for flat premium and offered a personal target of JPY 80B for 2026, above last year's JPY 74B, demonstrating confidence in sales momentum.

Max directly addressed that the reinsurance deal had minimal capital impact and explained ESR movement drivers including subsidiary dividends and yen rate sensitivity.

Virgil confirmed traditional individual VB flat to negative while group products up 14% overall (dental +48.8%, L&D +11.3%, group VB +11.7%). Focus for 2026 on unified experience across channels and continued investment in traditional business enrollment technology.

Max explained large in-force block with 93%+ persistency means new sales are small relative to total. COVID-era sales gap still closing. Expects lapses to exceed sales in 2026 but inflection within reasonable future.

Max clarified Tsumitasu was repriced, not Miraito. Moved discounted advanced premium rate from 25bp to 1%, a meaningful improvement driven by higher yields.

Koide explained new marketing/sales transformation enables concurrent 3-brand support. Dan cautioned some natural cannibalization of cancer sales when medical launches, as agents pivot to new product excitement. Koide added alliance partners sell cancer only, so won't be impacted by medical launch.

Yoshizumi confirmed aim to recover pre-COVID sales. Dan praised the marketing/sales shift and said they are better today than in a long time. Max cautioned earned premium still guided -1% to -2%.

Max firmly stated no fundamental changes to capital management or hedging philosophy. Put option program sized to cut 40-45 ESR points of FX tail risk.

Max identified dividends flowing from Japan to holding company as the missing piece that offset the benefit from higher JGB rates.

Max said no special dividend expected until ESR is formally implemented at end of Q1 2026, then will target 170-230% operating range.

Max attributed margin pressure primarily to NII headwinds from floating rate portfolio, while benefit ratio expected to decline over forecast period due to favorable third sector mix shift.

Khalaf declined to comment on speculation but highlighted LatAm on a path to $1 billion in earnings this year, led by Brazil.

McCallion said changes are incremental with no quick shifts, but higher rates provide positive momentum over time.

John highlighted asset-backed financing as showing strong relative value. Noted CML new origination spreads remain tight so they are being selective. Diversified platform enables flexibility.

John attributed the decline to seasonal U.S. entity dividend timing. Confirmed no change to capital trajectory, free cash flow ratio of 65-75%, and RBC at 379% well above 360% target.

John McCallion explained resegmentation created opportunity to rethink adjusted earnings reporting. Real estate depreciation exclusion better aligns with economic returns and operating cash flow. MetLife has higher real estate exposure than peers due to investment expertise.

John McCallion highlighted diversified MIM client base with ~$150B insurance AUM. Expects to maintain and grow Brighthouse relationship. Characterized worst-case scenario as very modest EPS impact given overall diversification. Emphasized PineBridge integration momentum and strong flows.

Ramy Tadros confirmed 230bps sequential improvement driven by dental seasonal pattern and pricing action benefits, plus normalized disability with strong recoveries from multiyear capability investments. Expects further Q4 improvement from dental seasonality to reach full 400bps combined improvement.

Ramy Tadros noted $14B+ YTD PRT with $12B in Q4 from jumbo deals. Cited balance sheet size, investment capabilities, and financial strength as competitive advantages. Takes M&A lens to capital deployment with ROEs supportive of enterprise targets. Deploying both own balance sheet and third-party capital.

Ramy Tadros isolated the pressure to 2 long-standing specialty clients with high-value injury claims, unrelated to macro factors or mental health trends. Disability PFOs are just above 10% of total Group Benefits, dental is approximately $5B.

John McCallion noted $200M+ CRE reserve increase is part of orderly loan resolution, typically indicative of trough stabilization. Expects resolution to pick up and peak this year. Impact of 2-5 RBC points, within normal excess capital levels with no impact on capital management.

Ramy Tadros confirmed both LTC and retail life underwriting were in line with expectations in MetLife Holdings, with no notable deviations.

Ramy Tadros explained the deal was priced through economic lens aligned with internal valuation. John McCallion noted cash flow impact is roughly the net of foregone earnings minus hedge cost savings. Transaction reduces VA balances by ~40%.

John McCallion provided detailed explanation of PE tailwinds from public equity markets and real estate stabilization driving higher VII assumptions.

Ramy addressed peer concerns directly, noting no material deviations in accident health and pointing to midpoint of range for 2025.

Sullivan said the roughly 6-7 emerging-market exits will predominantly be sales rather than shutdowns, prioritizing value maximization, and will take time to find the right buyers.

Sullivan emphasized the capital freed up will be well north of $3 billion, targeted at PGIM, Group Insurance and European Retirement over a roughly 5-year execution horizon, with other capital sources also available.

Del Frias provided specific assumptions: zero sales through November 5, gradual ramp to 50% average LP productivity in 2027, elevated surrenders throughout suspension.

Sullivan provided detailed breakdown of Gibraltar's diversified distribution including captive agents, independent agents, and bank channels, clarifying no systemic issues from POJ.

Andy confirmed continued recruiting. Two retention actions: enhanced training and development during 90 days, plus financial support for longer-term retention. Also emphasized taking right actions makes employees proud to work at Prudential, aiding retention.

Andy declined to confirm or deny FSA on-site investigation. Reiterated regular weekly interactions with FSA and voluntary nature of the sales suspension decision.

Yanela clarified 150% is the post-stress floor, not normal operating level. Normal operations at 180-200%. Different from peers due to different business mix. Result of considerable modeling and dialogue with rating agencies. Regulators focused on 100% threshold.

Andy confirmed planned succession was accelerated due to operational/compliance considerations. Brad Hearn is 30+ year veteran who led Prudential Advisors and architected LPL relationship. Japan sales up 4% YTD with 20% from new products.

Yanela explained three drivers: assumption update impact on premium line (over half the change), continuing surrender impact on recurring-pay products, and product mix shift to retirement/savings booked in policy charges not premiums. Account balances up $2B sequentially.

Yanela distinguished PRU's strict JFSA specification interpretation from peers using internal models. Key sensitivity: Japanese rate increases causing lapse risk. 50bp rate rise + 10% equity decline still wouldn't make ESR binding.

Yanela confirmed no expected change to dividend capacity from ESR. Roughly 70% of U.S. dollar liabilities in Japan already reinsured outside Japan. Product strategy influenced to be ESR-friendly.

Andy reframed de-risking as continuous rather than event-based. Stated nothing currently in the pipeline worthy of discussing but signaled ongoing evaluation.

Yanela explained realized gains/losses impact both GAAP and statutory, making net income a better near-term cash flow proxy.

Yanela explained near-term strain from new business distribution costs and runoff headwinds, noting 5-8% growth is achieved despite these drags.

Clarified wrap flows are only one component of the $19B total client outflows but declined to break out the exact Comerica portion.

Jim explained departures are isolated, some RIA moves, some competitor checks. Net recruiting was positive last year. Departures are lumpy but not systemic. Emphasized sustainable growth from 10,000-adviser organic base.

Walter described it as a 10-year growing deal with strong adviser base and very good IRRs within target ranges. Stability and growth potential differentiate it from one-off recruiting deals.

Walter expressed comfort with core margin performance. Interest impact minimized by investment repositioning. Range is good barring external factors like government policy or rate changes.

Jim acknowledged some losses are inevitable given competitor offers but emphasized strong adviser satisfaction. Recruits from all channels report significant growth after joining Ameriprise.

Walter attributed to both frequency and large claims, said it's within normal range with nothing exceptional. Jim confirmed no longer-term impact expected.

Jim gave a noncommittal answer about payout grid, emphasizing balanced equation of support plus compensation. Not ready to discuss specifics but acknowledged periodic adjustments are normal.

Walter confirmed some carryover into Q4 from the two departures but attrition patterns otherwise stable. No broad retention concern.

Walter attributed strength to favorable life claims. On risk transfer, bid-ask spread hasn't changed enough to justify a deal from shareholder perspective.

Jim confirmed net adviser count is up. Emphasized 10,000-adviser base, productivity focus, strong profitability balance. Not looking to add headcount at any cost.

Jim noted one more Limestone tranche to exit but no other large institutional losses expected. The Q1 passive repositioning was a specific international client situation.

Jim firmly denied any retention issues. Headcount is actually up. Highest attrition from retirements and practice transitions. Removed disclosure to match industry peers.

Darden said the DTC pressure is not carrier competition but lower paid-search volume raising cost per click; Globe Life will join AI-embedded ads without giving up margin, aided by agency lead conversion.

Kalmbach guided underlying health margin to about 25% in Q3 and 24% in Q4 (a 23-25% range) excluding the assumption update, a modest improvement from Q2's roughly 23%.

Normalized life margins progressed from 38% (2023) to 39.7% (2024) to 41% (2025). Q3 specifically at 41.5%. Assumption change lowered reserves, indicating improved future profit outlook. Ongoing remeasurement gains expected if recent favorable experience continues.

High end of 2026 range ($15.30) contemplates potential further assumption updates. Low end does not. Guidance range width reflects this scenario analysis approach.

Estimated 3-5 year ramp to full $200M run rate. Not year-1 but not 10-year either. Final timing depends on regulatory approval and rating agency discussions to be completed Q3.

Two big components: deferred acquisition cost treatment differences between GAAP and statutory, plus reserving methodology differences. Not mortality-related.

Assumes utilization stays elevated at Q1 levels but moderates slightly in H2 as deductibles are used up. Premium rate increases not reflected in Q1 obligations.

Favorable mortality helps stat results but ~$75M less benefit from reserve valuation manual changes vs 2024. $60-100M assumption update is GAAP only but favorable claims flow through stat.

Confirmed Bermuda is a sustainable capital management strategy, not one-time. Self-funded without third-party sidecar capital.

Annual process: Q3 determination, file with states, rates effective end-Q1/beginning-Q2 following year. Expect to catch up on utilization by 2026 assuming trends don't worsen.

Chris noted Q1 2026 benefited from strong Q4 momentum continuing with multiple large case wins versus Q1 2025 large case loss. Significant difference in transfer deposit growth. Large segment lumpy, SMB steady and strong.

Kamal noted numbers exclude strong private market performance including #1 ranked real estate strategy. Core weakness in active US equities with strong long-term numbers but short-term underperformance. Non-US fixed income particularly strong. Products designed to be different from index which creates deviation in volatile markets.

Deanna attributed to post-strategic-review focus on capital-efficient businesses with strong value of new business metrics. Joel noted normalized run rate around 85% after adjusting noncash items in denominator. Mix of business provides flexibility and optionality for capital deployment. High bar applied to both organic and inorganic deployment.

Amy detailed dual drivers: dental pricing actions flowing through since late 2025, plus dental network optimization showing up in 2026. Expects loss ratio to move into very high sixties as longer-term run rate. More improvement in 2026 than full-year 2025. Bundled approach remains key to market positioning.

Kamal cited CRE in strongest position in 3 years with improving occupancy, pricing power and capital flows. Transaction volume up 17% YTD. Managers without redemption queues will gain market share by deploying fresh capital at better valuations. Principal's institutional book and insurance alignment provide structural advantage.

Deanna emphasized unchanged disciplined approach: strategic alignment, capability enhancement, financial targets met, cultural fit. Organic targets achievable without M&A. Scale recognized as critical but high bar for any capital deployment. Successfully integrated Wells Fargo acquisition and now on front foot for growth.

Joel cited 140bp enterprise margin expansion year over year and 80bp on trailing twelve months. During April volatility they focused on controllable expenses. Practice of aligning expenses with revenue will continue.

Chris explained IO had more maturities in 2025 with fewer issuances but business is opportunistic. PRT was moderate at $445M due to smaller pipeline and disciplined return requirements. Full year PRT outlook dependent on second half pipeline.

Chris broke down SMB vs large dynamics. SMB consistently strong with 30% transfer deposit growth. Large more lumpy. Fee rate down ~3bp, 1bp from market outperformance, rest from VA mix shift.

Amy explained Q1 2024 had one-time reclassification from group disability to supplemental health. Underlying supplemental health growing at double the rate of other products.